129
Views
14
CrossRef citations to date
0
Altmetric
Research Article

Treatment of Idiopathic Orbital Inflammatory Disease with Cyclosporine-A: A Case Presentation

, , &
Pages 260-261 | Received 28 Sep 2009, Accepted 03 Nov 2009, Published online: 02 Dec 2009

REFERENCES

  • Jacobs D, Galetta S.Diagnosis and management of orbital pseudotumor. Curr Opin Ophthalmol. 2002;13(6):347–51.
  • Mombaerts I, Schlingemann RO, Goldschmeding R, Koornneef L. Are systemic corticosteroids useful in the management of orbital pseudotumor? Ophthalmology. 1996;103:521–7.
  • Mihatsch MJ, Steiner K, Abeywickrama KH, et al. Risk factors for the development of chronic Cyclosporine-nephrotoxicity. Clin Nephrol. 1988;29:165–75.
  • Miescher PA, Favre H, Chatelanat F, Mihatsch MJ. Combined steroid- Cyclosporine treatment of chronic autoimmune diseases. Clinical results and assessment of nephrotoxicity by renal biopsy. Klin Wochenschr. 1987;65:727–36.
  • Feutren G, Mihatsch MJ.Risk factors for Cyclosporine- induced nephrotoxicity in patients with autoimmune diseases. N Engl J Med. 1992;326:1654–60.
  • Bielory L, Frohman PL. Low-dose Cyclosporine therapy of granulomatous optic neuropathy and orbitopathy. Ophthalmology. 1991;98:1732–5.
  • Sánchez-Román J, Varela-Aguilar JM, Bravo-Ferrer J, et al.Idiopathic orbital myositis: treatment with Cyclosporine. Ann Rheum Dis. 1993;52:84–85.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.